PD-L1 expression in human placentas and gestational trophoblastic diseases

International Journal of Gynecological Pathology

Volumn 36, Issue 2, 2017, Pages 146-153

  Veras, Emanuela ^a,b   Kurman, Robert J ^a,b   Wang, Tian Li ^a,b   Shih, Ie Ming ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Choriocarcinoma; Gestational; PD 1; PD L1; Trophoblast

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ABORTION; ARTICLE; BRAIN; BREAST; CHORIOCARCINOMA; CHORION; CHORION VILLUS; CONTROLLED STUDY; CYTOTROPHOBLAST; FEMALE; GALLBLADDER; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; KIDNEY; LARGE INTESTINE; LUNG; LYMPH NODE; LYMPHOCYTE; PANCREAS; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SALIVARY GLAND; SMALL INTESTINE; STOMACH; SYNCYTIOTROPHOBLAST; TONSIL; TROPHOBLAST; TROPHOBLASTIC TUMOR; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; METABOLISM; PATHOLOGY; PREGNANCY;

ANTIGENS, CD274; BIOMARKERS, TUMOR; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PLACENTA; PREGNANCY;

EID: 84976550020     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000305     Document Type: Article

References (32)

1. Fraccaroli L, Alfieri J, Larocca L, et al. A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation. Hum Reprod 2009; 24: 166-75.
2. Singer G, Kurman RJ, McMaster M, et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002; 26: 914-20.
3. Tilburgs T, Evans JH, Crespo AC, et al. The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface. Proc Natl Acad Sci USA 2015; 112: 13312-7.
4. Pazmany L, Mandelboim O, Vales-Gomez M, et al. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996; 274: 792-5.
5. Poehlmann TG, Schaumann A, Busch S, et al. Inhibition of term decidual NK cell cytotoxicity by soluble HLA-G1. Am J Reprod Immunol 2006; 56: 275-85.
6. Long EO, Kim HS, Liu D, et al. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31: 227-58.
7. Habicht A, Dada S, Jurewicz M, et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol 2007; 179: 5211-9.
8. Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351-6.
9. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: Cell-To-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109: 2040-8.
10. Ban Y, Chang Y, Dong B, et al. Indoleamine 2,3-dioxygenase levels at the normal and recurrent spontaneous abortion fetalmaternal interface. J Int Med Res 2013; 41: 1135-49.
11. Taglauer ES, Trikhacheva AS, Slusser JG, et al. Expression and function of PDCD1 at the human maternal-fetal interface. Biol Reprod 2008; 79: 562-9.
12. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23: 2965-70.
13. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28.
14. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847-56.
15. D'Addio F, Riella LV, Mfarrej BG, et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 2011; 187: 4530-41.
16. Shih Ie M. Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets. Lancet Oncol 2007; 8: 642-50.
17. Benirschke K, Burton GJ, Baergen RN, eds. Basic structure of the villous trees. Pathology of the Human Placenta, 6th ed. Heidelberg: Springer; 2012: 55-100.
18. Shih I-M, Mazur M, Kurman RJ. Gestational trophoblastic tumors and related tumro-like lesions. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Balustein's Pathology of the Female Genital Tract. Heidelberg: Springer; 2011: 1075-1136.
19. Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: A new challenging role for regulatory T cells. Placenta 2014; 35: 241-8.
20. Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNgamma That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 2016; 76: 1031-43.
21. Tuncer ZS, Vegh GL, Fulop V, et al. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 2000; 77: 389-93.
22. Murphy SP, Tayade C, Ashkar AA, et al. Interferon gamma in successful pregnancies. Biol Reprod 2009; 80: 848-59.
23. Sotnikova N, Voronin D, Antsiferova Y, et al. Interaction of decidual CD56+ NK with trophoblast cells during normal pregnancy and recurrent spontaneous abortion at early term of gestation. Scand J Immunol 2014; 80: 198-208.
24. Bellucci R, Martin A, Bommarito D, et al. Interferon-gammainduced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4: E1008824.
25. Rabreau M, Rouas-Freiss N, Landi M, et al. HLA-G expression in trophoblast cells is independent of embryonic development. Hum Immunol 2000; 61: 1108-12.
26. Sheu JJ, Shih Ie M. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol 2007; 17: 436-43.
27. Gregori S, Amodio G, Quattrone F, et al. HLA-G Orchestrates the Early Interaction of Human Trophoblasts with the Maternal Niche. Front Immunol 2015; 6: 128.
28. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189: 1093-100.
29. Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: Decidua-Associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA 1999; 96: 5674-9.
30. Wang SC, Li YH, Piao HL, et al. PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy. Cell Death Dis 2015; 6: E1738.
31. Hui P, Baergen R, Cheung ANY, et al. Gestational trophoblastic disease. In: Kurman RJ, Carcangiu ML, Young RH, eds. WHO Classification of Tumorus of Female Reproductive Organs. Lyon: WHO; 2014: 155-68.
32. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.